India, Aug. 21 -- Arcturus Therapeutics Holdings Inc. (ARCT), a messenger RNA medicines company focused on liver and respiratory rare diseases, recently reported second-quarter 2026 financial results and provided pipeline updates.
The company highlighted continued progress in its rare disease programs and the return of global rights to KOSTAIVE and its broader infectious disease vaccine portfolio.
Q2 Financial Results:
The company's net loss increased to $23.8 million, or $0.84 per share, in the second quarter of 2026, compared with a net loss of $9.2 million, or $0.34 per share, in the prior-year quarter.
Revenue from strategic alliances and collaborations declined to $3.0 million from $28.3 million, primarily due to lower revenue reco...